Tetra Bio-Pharma Company Description
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology.
The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia.
It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma.
Tetra Bio-Pharma Inc. has an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug.
The company is headquartered in Orléans, Canada.
| Country | Canada |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
Contact Details
Address: 2316 St. Joseph Boulevard Orléans, K1C 1E8 Canada | |
| Website | tetrabiopharma.com |
Stock Details
| Ticker Symbol | TBPMQ |
| Exchange | OTCMKTS |
| Share Class | Class A Shares |
| Fiscal Year | December - November |
| Reporting Currency | CAD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Richard Giguere | Chief Executive Officer of Tetra Natural Health Inc. |
| Steeve Néron | Chief Commercial Officer |
| André Rancourt B.Sc. | Co-Founder |
| Leslie Auld C.A., C.P.A., CA, CPA, M.B.A., MBA | Chief Financial Officer |
| Jennifer McCaughey | Vice President of Investor Relations |
| Dania Scott B.Sc. | Senior Vice President of Commercial Strategy |
| Aurelia De Pauw | Senior Vice President of Clinical Programs and Medical Affairs |
| Randy Ringuette | Project Director and Member of Advisory Board |
| Chris MacLean | Chief Operating Officer of Tetra Natural Health |